TELA Bio (TELA) Financials

TELA Bio logo
$0.69 -0.04 (-5.27%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.70 +0.01 (+0.94%)
As of 11/20/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for TELA Bio

Annual Income Statements for TELA Bio

This table shows TELA Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-30 -30 -29 -33 -44 -47 -38 -39
Consolidated Net Income / (Loss)
-21 -22 -29 -33 -44 -47 -38 -39
Net Income / (Loss) Continuing Operations
-21 -22 -29 -33 -44 -47 -38 -39
Total Pre-Tax Income
-21 -22 -29 -33 -44 -47 -38 -39
Total Operating Income
-18 -19 -25 -29 -39 -44 -34 -34
Total Gross Profit
2.94 9.27 11 19 27 40 46 54
Total Revenue
8.27 15 18 29 41 58 69 80
Operating Revenue
8.27 15 18 29 41 58 69 80
Total Cost of Revenue
5.33 6.17 6.68 11 14 18 23 26
Operating Cost of Revenue
5.33 6.17 6.68 11 14 18 23 26
Total Operating Expenses
21 28 37 48 66 84 81 88
Selling, General & Admin Expense
4.90 6.22 10 12 14 15 15 16
Marketing Expense
14 18 22 29 43 60 65 63
Research & Development Expense
4.34 4.15 4.26 6.74 8.94 9.62 8.81 9.22
Total Other Income / (Expense), net
-3.31 -3.26 -3.56 -3.83 -5.29 -2.59 -3.87 -4.85
Interest Expense
3.62 3.61 3.56 3.60 5.28 5.22 5.29 6.13
Other Income / (Expense), net
0.31 0.35 - -0.23 -0.01 2.63 1.42 1.29
Income Tax Expense
- - - - 0.00 0.00 -0.14 0.23
Basic Earnings per Share
($101.41) ($17.10) ($2.23) ($2.30) ($2.72) ($2.04) ($1.33) ($0.83)
Weighted Average Basic Shares Outstanding
294.99K 1.77M 12.93M 14.47M 16.27M 22.87M 28.53M 46.95M
Diluted Earnings per Share
($101.41) ($17.10) ($2.23) ($2.30) ($2.72) ($2.04) ($1.33) ($0.83)
Weighted Average Diluted Shares Outstanding
294.99K 1.77M 12.93M 14.47M 16.27M 22.87M 28.53M 46.95M
Weighted Average Basic & Diluted Shares Outstanding
294.99K 1.77M 12.93M 14.55M 19.22M 24.65M 39.55M 44.74M

Quarterly Income Statements for TELA Bio

This table shows TELA Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 22 - - - 20
Net Income / (Loss) Attributable to Common Shareholders
-5.66 -13 -10 -9.21 -11 -9.92 -8.60 -9.04 -12 -11 -9.30
Consolidated Net Income / (Loss)
-5.66 -13 -10 -9.21 -11 -9.92 -8.60 -9.04 -12 -11 -9.30
Net Income / (Loss) Continuing Operations
-5.66 -13 -10 -9.21 -11 -9.92 -8.60 -9.04 -12 -11 -9.30
Total Pre-Tax Income
-5.66 -13 -10 -9.35 -11 -9.89 -8.60 -8.90 -12 -11 -9.20
Total Operating Income
-4.83 -12 -9.37 -8.35 -10 -9.08 -7.55 -6.65 -11 -9.28 -7.29
Total Gross Profit
11 11 13 11 13 14 14 14 13 14 12
Total Revenue
17 16 19 18 19 20 21 21 19 19 19
Operating Revenue
17 16 19 18 19 20 21 21 19 19 19
Total Cost of Revenue
5.27 5.02 6.10 6.43 5.91 6.00 6.63 6.73 6.44 5.25 6.56
Operating Cost of Revenue
5.27 5.02 6.10 6.43 5.91 6.00 6.63 6.73 6.44 5.25 6.56
Total Operating Expenses
16 23 22 20 23 23 22 20 23 23 20
Selling, General & Admin Expense
3.83 3.62 3.68 3.59 3.84 4.13 4.11 3.78 4.17 4.06 4.99
Marketing Expense
18 17 16 14 17 17 15 14 17 16 13
Research & Development Expense
2.39 2.32 2.07 2.03 2.54 2.20 2.35 2.13 2.34 2.72 1.60
Total Other Income / (Expense), net
-0.84 -1.03 -1.01 -1.00 -0.74 -0.81 -1.05 -2.25 -1.69 -1.92 -1.91
Interest Expense
1.33 1.33 1.34 1.28 1.22 1.19 1.20 2.53 2.05 2.08 2.10
Other Income / (Expense), net
0.50 0.30 0.34 0.29 0.48 0.38 0.15 0.28 0.37 0.16 0.19
Income Tax Expense
0.00 0.00 0.00 - 0.05 0.03 0.00 0.15 0.06 0.06 0.10
Basic Earnings per Share
($0.23) ($0.51) ($0.42) ($0.17) ($0.25) ($0.22) ($0.19) ($0.17) ($0.21) ($0.20) ($0.16)
Weighted Average Basic Shares Outstanding
24.58M 24.66M 24.70M 28.53M 45.27M 45.37M 45.42M 46.95M 57.26M 57.41M 57.69M
Diluted Earnings per Share
($0.23) ($0.51) ($0.42) ($0.17) ($0.25) ($0.22) ($0.19) ($0.17) ($0.21) ($0.20) ($0.16)
Weighted Average Diluted Shares Outstanding
24.58M 24.66M 24.70M 28.53M 45.27M 45.37M 45.42M 46.95M 57.26M 57.41M 57.69M
Weighted Average Basic & Diluted Shares Outstanding
24.66M 24.71M 39.39M 39.55M 39.55M 39.62M 40.34M 44.74M 44.77M 44.89M 45.19M

Annual Cash Flow Statements for TELA Bio

This table details how cash moves in and out of TELA Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
5.93 28 29 -30 -1.91 4.98 5.94 -1.84
Net Cash From Operating Activities
-20 -26 -24 -30 -41 -41 -42 -28
Net Cash From Continuing Operating Activities
-20 -26 -24 -30 -41 -41 -42 -28
Net Income / (Loss) Continuing Operations
-21 -22 -29 -33 -44 -47 -38 -39
Consolidated Net Income / (Loss)
-21 -22 -29 -33 -44 -47 -38 -39
Depreciation Expense
0.46 0.28 0.22 0.23 0.38 0.43 0.63 0.63
Amortization Expense
0.79 0.30 0.30 0.30 0.80 0.38 0.38 0.38
Non-Cash Adjustments To Reconcile Net Income
4.35 2.56 3.90 5.78 8.12 6.67 0.07 8.18
Changes in Operating Assets and Liabilities, net
-4.48 -6.24 -0.09 -3.47 -5.76 -1.67 -4.83 1.42
Net Cash From Investing Activities
-1.56 -12 9.12 -0.63 -1.87 -0.60 4.45 0.85
Net Cash From Continuing Investing Activities
-1.56 -12 9.12 -0.63 -1.87 -0.60 4.45 0.85
Purchase of Property, Plant & Equipment
-0.06 -0.20 -0.17 -0.63 -0.87 -0.61 -0.99 -0.45
Sale of Property, Plant & Equipment
0.00 - - 0.00 0.00 0.01 5.44 1.29
Net Cash From Financing Activities
27 66 44 0.59 41 46 43 26
Net Cash From Continuing Financing Activities
27 66 44 0.59 41 46 43 26
Repayment of Debt
-20 - 0.00 0.00 -33 0.00 0.00 -46
Issuance of Debt
44 51 0.00 0.00 40 0.00 0.00 60
Issuance of Common Equity
0.00 0.00 45 0.04 0.05 0.09 0.28 0.11
Other Financing Activities, net
0.01 0.01 0.18 0.55 34 46 43 12
Effect of Exchange Rate Changes
0.00 -0.00 0.02 0.01 -0.14 0.16 0.03 -0.22
Cash Interest Paid
1.09 3.09 2.98 2.93 3.39 4.62 4.07 4.72

Quarterly Cash Flow Statements for TELA Bio

This table details how cash moves in and out of TELA Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-9.59 -11 -9.20 35 -9.84 -7.86 -5.28 21 -11 -9.17 -7.76
Net Cash From Operating Activities
-14 -11 -8.98 -7.53 -9.73 -7.91 -5.72 -4.87 -11 -9.38 -8.69
Net Cash From Continuing Operating Activities
-14 -11 -8.98 -7.53 -9.73 -7.91 -5.72 -4.87 -11 -9.38 -8.69
Net Income / (Loss) Continuing Operations
-5.66 -13 -10 -9.21 -11 -9.92 -8.60 -9.04 -12 -11 -9.30
Consolidated Net Income / (Loss)
-5.66 -13 -10 -9.21 -11 -9.92 -8.60 -9.04 -12 -11 -9.30
Depreciation Expense
0.14 0.15 0.17 0.17 0.17 0.18 0.15 0.13 0.17 0.17 0.17
Amortization Expense
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Non-Cash Adjustments To Reconcile Net Income
-5.81 1.57 1.97 2.48 1.92 1.37 2.02 2.93 2.08 1.20 1.64
Changes in Operating Assets and Liabilities, net
-3.14 0.08 -0.85 -1.07 -0.65 0.38 0.61 1.02 -1.24 0.42 -1.30
Net Cash From Investing Activities
4.70 0.07 -0.12 -0.19 0.14 0.20 0.31 0.19 0.19 0.24 1.02
Net Cash From Continuing Investing Activities
4.70 0.07 -0.12 -0.19 0.14 0.20 0.31 0.19 0.19 0.24 1.02
Purchase of Property, Plant & Equipment
-0.30 -0.30 -0.12 -0.26 -0.03 -0.11 -0.21 -0.09 -0.12 -0.06 -0.01
Sale of Property, Plant & Equipment
5.00 0.37 - 0.07 0.17 0.32 0.52 0.28 0.31 0.30 1.02
Net Cash From Financing Activities
0.06 -0.01 0.10 43 -0.12 -0.00 0.02 26 -0.30 -0.02 -0.05
Net Cash From Continuing Financing Activities
0.06 -0.01 0.10 43 -0.12 -0.00 0.02 26 -0.30 -0.02 -0.05
Issuance of Common Equity
0.16 - 0.12 - 0.06 - 0.05 - 0.03 - 0.02
Other Financing Activities, net
-0.11 -0.01 -0.02 43 -0.18 -0.00 -0.02 12 -0.08 -0.02 -0.07
Effect of Exchange Rate Changes
0.05 -0.01 -0.19 0.18 -0.13 -0.15 0.10 -0.04 -0.03 -0.01 -0.03
Cash Interest Paid
1.18 1.18 1.19 0.52 1.37 1.30 1.31 0.74 1.82 1.84 1.86

Annual Balance Sheets for TELA Bio

This table presents TELA Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
27 68 86 63 68 78 87 81
Total Current Assets
23 64 83 59 62 72 78 76
Cash & Equivalents
17 45 74 44 42 47 53 51
Accounts Receivable
1.30 2.84 2.68 4.23 6.62 9.74 10 10
Inventories, net
4.35 4.60 3.91 7.66 12 13 13 11
Prepaid Expenses
0.33 2.31 2.24 3.23 2.02 2.10 2.52 3.37
Plant, Property, & Equipment, net
0.76 0.68 0.63 1.19 1.68 1.98 2.34 2.23
Total Noncurrent Assets
3.22 2.91 2.61 2.30 3.73 4.34 6.16 3.61
Intangible Assets
- 2.91 2.61 2.30 2.50 2.12 1.74 1.36
Other Noncurrent Operating Assets
0.00 - - 0.00 1.23 2.22 4.28 2.25
Total Liabilities & Shareholders' Equity
27 68 86 63 68 78 87 81
Total Liabilities
41 37 37 42 54 59 58 75
Total Current Liabilities
9.56 6.71 6.61 11 12 17 16 18
Short-Term Debt
- - - - - - - 0.00
Accounts Payable
3.42 3.17 0.65 2.41 1.53 1.67 2.15 2.31
Accrued Expenses
5.15 3.54 5.95 8.16 11 15 13 16
Total Noncurrent Liabilities
31 30 31 32 41 42 43 57
Long-Term Debt
- 30 31 0.00 40 41 41 56
Other Noncurrent Operating Liabilities
1.65 0.00 0.00 0.38 1.23 1.69 1.39 1.48
Total Equity & Noncontrolling Interests
-138 31 49 20 14 19 28 6.31
Total Preferred & Common Equity
-138 31 49 20 14 19 28 6.31
Preferred Stock
- 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-138 31 49 20 14 19 28 6.31
Common Stock
- 199 246 250 288 340 387 404
Retained Earnings
-138 -168 -197 -230 -274 -321 -359 -398
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.02 -0.07 -0.05 0.15 0.09 0.09 0.09

Quarterly Balance Sheets for TELA Bio

This table presents TELA Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
87 72 60 53 77 68 62 70 60 49
Total Current Assets
82 63 51 44 70 61 56 64 54 45
Cash & Equivalents
58 37 26 17 43 35 30 40 30 23
Accounts Receivable
8.07 9.96 9.10 11 11 11 11 9.72 9.64 9.27
Inventories, net
14 14 13 14 14 11 12 12 11 12
Prepaid Expenses
1.66 1.92 2.14 2.01 2.82 3.16 3.50 2.83 3.37 1.05
Plant, Property, & Equipment, net
1.75 2.33 2.35 2.42 2.20 2.17 2.21 2.16 2.05 1.88
Total Noncurrent Assets
3.32 6.89 6.75 6.46 5.31 4.63 3.33 3.43 3.20 3.01
Intangible Assets
2.21 2.02 1.93 1.83 1.64 1.55 1.45 1.26 1.17 1.07
Other Noncurrent Operating Assets
1.10 4.87 4.82 4.63 3.57 3.01 1.81 2.17 2.03 1.94
Total Liabilities & Shareholders' Equity
87 72 60 53 77 68 62 70 60 49
Total Liabilities
57 57 57 59 59 58 60 75 76 74
Total Current Liabilities
15 15 15 17 17 19 17 18 18 73
Short-Term Debt
- - - - - 3.33 - - - 56
Accounts Payable
3.09 3.36 2.31 2.48 4.00 1.74 2.37 3.89 2.88 2.39
Accrued Expenses
12 12 13 14 13 14 15 14 15 14
Total Noncurrent Liabilities
41 42 42 42 43 39 43 57 57 1.21
Long-Term Debt
40 41 41 41 41 38 41 56 56 0.00
Other Noncurrent Operating Liabilities
1.07 1.61 1.53 1.46 1.32 1.24 1.56 1.39 1.31 1.21
Total Equity & Noncontrolling Interests
31 14 2.87 -6.27 18 9.18 1.56 -5.20 -16 -25
Total Preferred & Common Equity
31 14 2.87 -6.27 18 9.18 1.56 -5.20 -16 -25
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
31 14 2.87 -6.27 18 9.18 1.56 -5.20 -16 -25
Common Stock
338 341 342 343 388 389 390 405 405 406
Retained Earnings
-308 -327 -339 -350 -370 -380 -389 -410 -421 -430
Accumulated Other Comprehensive Income / (Loss)
0.14 0.10 0.10 0.15 0.09 0.09 0.09 0.09 0.08 0.08

Annual Metrics And Ratios for TELA Bio

This table displays calculated financial ratios and metrics derived from TELA Bio's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 11,405,543.00 14,432,285.00 14,503,570.00 19,159,145.00 24,488,803.00 - 40,341,535.00
DEI Adjusted Shares Outstanding
0.00 11,405,543.00 14,432,285.00 14,503,570.00 19,159,145.00 24,488,803.00 - 40,341,535.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -2.65 -2.00 -2.29 -2.31 -1.91 - -0.96
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 86.68% 17.91% 61.77% 40.58% 41.13% 18.56% 15.84%
EBITDA Growth
0.00% -12.42% -35.74% -17.75% -29.80% -7.41% 22.03% 0.71%
EBIT Growth
0.00% -7.72% -34.33% -17.42% -31.46% -6.21% 21.10% 0.69%
NOPAT Growth
0.00% -7.76% -31.90% -16.52% -32.45% -12.99% 22.60% 1.06%
Net Income Growth
0.00% -6.32% -28.40% -15.57% -33.12% -5.35% 18.91% -2.62%
EPS Growth
0.00% 83.14% 86.96% -3.14% -18.26% 25.00% 34.80% 37.59%
Operating Cash Flow Growth
0.00% -28.10% 4.18% -24.44% -33.90% -0.27% -1.81% 32.16%
Free Cash Flow Firm Growth
0.00% 0.00% 22.33% -37.99% -39.60% 1.67% 10.19% 36.58%
Invested Capital Growth
0.00% 627.33% -17.51% 40.28% 59.34% 3.81% 33.51% -34.24%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 10.12% 8.51% 10.13% 0.95% 4.18%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -4.06% -4.78% -0.62% 10.15% 5.00%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -3.98% -4.82% -0.50% 9.61% 4.97%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -3.18% -4.80% -6.88% 10.32% 4.81%
Net Income Q/Q Growth
0.00% 0.00% 0.00% -2.55% -3.17% -6.65% 8.87% 0.43%
EPS Q/Q Growth
0.00% 0.00% 0.00% -2.68% 5.23% -2.51% 19.88% 0.00%
Operating Cash Flow Q/Q Growth
0.00% -5.89% 0.33% -8.89% -3.54% -0.17% 7.80% 8.62%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -8.00% 4.34% 10.17% 14.09%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 41.61% 38.02% -0.36% -2.79% -16.62%
Profitability Metrics
- - - - - - - -
Gross Margin
35.56% 60.03% 61.68% 63.85% 65.30% 68.62% 67.08% 67.69%
EBITDA Margin
-196.04% -118.05% -135.89% -98.92% -91.34% -69.51% -45.72% -39.19%
Operating Margin
-214.91% -124.06% -138.77% -99.96% -94.18% -75.40% -49.23% -42.05%
EBIT Margin
-211.12% -121.82% -138.77% -100.73% -94.20% -70.90% -47.18% -40.45%
Profit (Net Income) Margin
-254.92% -145.18% -158.10% -112.94% -106.95% -79.83% -54.60% -48.37%
Tax Burden Percent
100.00% 100.00% 100.91% 100.00% 100.00% 100.00% 99.62% 100.60%
Interest Burden Percent
120.75% 119.18% 112.90% 112.12% 113.53% 112.60% 116.18% 118.89%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -500.22% -292.99% -314.34% -274.97% -248.12% -161.47% -168.58%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -348.62% -260.30% -269.13% -41.31% 132.10% -4.26% 282.67%
Return on Net Nonoperating Assets (RNNOA)
0.00% 240.25% 221.00% 218.06% 17.46% -33.11% 1.60% -54.78%
Return on Equity (ROE)
153.84% -259.97% -72.00% -96.28% -257.51% -281.23% -159.87% -223.35%
Cash Return on Invested Capital (CROIC)
0.00% -321.64% -273.80% -347.86% -320.73% -251.86% -190.17% -127.26%
Operating Return on Assets (OROA)
-64.16% -39.55% -32.74% -39.84% -59.84% -56.81% -39.72% -38.66%
Return on Assets (ROA)
-77.47% -47.14% -37.30% -44.67% -67.94% -63.97% -45.97% -46.23%
Return on Common Equity (ROCE)
1,546.97% 1,610.84% -72.00% -96.28% -257.51% -281.23% -159.87% -223.35%
Return on Equity Simple (ROE_SIMPLE)
15.30% -72.43% -58.73% -165.57% -309.65% 0.00% -132.97% 0.00%
Net Operating Profit after Tax (NOPAT)
-12 -13 -18 -21 -27 -31 -24 -24
NOPAT Margin
-150.44% -86.84% -97.14% -69.97% -65.93% -52.78% -34.46% -29.43%
Net Nonoperating Expense Percent (NNEP)
69.41% -151.60% -32.69% -45.21% -233.67% -380.22% -157.21% -451.25%
Return On Investment Capital (ROIC_SIMPLE)
- - - - -50.36% -51.94% -34.32% -38.13%
Cost of Revenue to Revenue
64.44% 39.97% 36.65% 36.15% 34.70% 30.73% 32.92% 31.83%
SG&A Expenses to Revenue
59.21% 40.29% 55.69% 42.29% 33.47% 25.47% 21.24% 19.55%
R&D to Revenue
52.44% 26.87% 23.36% 22.89% 21.58% 16.46% 12.72% 11.49%
Operating Expenses to Revenue
250.47% 184.09% 200.46% 163.81% 159.47% 144.03% 116.31% 109.74%
Earnings before Interest and Taxes (EBIT)
-17 -19 -25 -30 -39 -41 -33 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-16 -18 -25 -29 -38 -41 -32 -31
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 4.77 4.43 9.24 15.40 8.59 4.18 7.54
Price to Tangible Book Value (P/TBV)
0.00 5.27 4.68 10.43 18.66 9.67 4.45 9.61
Price to Revenue (P/Rev)
6.28 9.56 11.92 6.30 5.32 2.77 1.72 0.59
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 18.64 31.78 18.51 17.88 12.31 6.35 4.71
Enterprise Value to Revenue (EV/Rev)
19.20 7.99 9.53 4.81 5.27 2.67 1.55 0.65
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 0.98 0.63 0.00 2.79 2.15 1.45 8.82
Long-Term Debt to Equity
0.00 0.98 0.63 0.00 2.79 2.15 1.45 8.82
Financial Leverage
-0.91 -0.69 -0.85 -0.81 -0.42 -0.25 -0.38 -0.19
Leverage Ratio
-1.99 5.52 1.93 2.16 3.79 4.40 3.48 4.83
Compound Leverage Factor
-2.40 6.57 2.18 2.42 4.30 4.95 4.04 5.74
Debt to Total Capital
0.00% 49.41% 38.60% 0.00% 73.62% 68.21% 59.10% 89.81%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 49.41% 38.60% 0.00% 73.62% 68.21% 59.10% 89.81%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-905.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
1,005.54% 50.59% 61.40% 100.00% 26.38% 31.79% 40.90% 10.19%
Debt to EBITDA
0.00 -1.66 -1.25 0.00 -1.06 -1.00 -1.30 -1.77
Net Debt to EBITDA
0.00 1.34 1.76 0.00 0.06 0.15 0.36 -0.15
Long-Term Debt to EBITDA
0.00 -1.66 -1.25 0.00 -1.06 -1.00 -1.30 -1.77
Debt to NOPAT
0.00 -2.25 -1.74 0.00 -1.46 -1.31 -1.72 -2.36
Net Debt to NOPAT
0.00 1.81 2.46 0.00 0.08 0.20 0.48 -0.20
Long-Term Debt to NOPAT
0.00 -2.25 -1.74 0.00 -1.46 -1.31 -1.72 -2.36
Altman Z-Score
-7.54 -0.73 0.60 -2.69 -3.59 -4.27 -4.15 -5.94
Noncontrolling Interest Sharing Ratio
-905.54% 719.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
2.43 9.58 12.60 5.58 5.03 4.23 5.01 4.20
Quick Ratio
1.94 8.55 11.67 4.55 3.92 3.33 4.02 3.40
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -21 -17 -23 -32 -31 -28 -18
Operating Cash Flow to CapEx
-34,351.72% -12,955.84% -14,644.31% -4,853.59% -4,672.94% -6,820.87% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -5.90 -4.64 -6.34 -6.03 -6.00 -5.32 -2.91
Operating Cash Flow to Interest Expense
-5.50 -7.07 -6.86 -8.46 -7.72 -7.82 -7.86 -4.60
Operating Cash Flow Less CapEx to Interest Expense
-5.51 -7.13 -6.91 -8.63 -7.88 -7.94 -7.02 -4.46
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.30 0.32 0.24 0.40 0.64 0.80 0.84 0.96
Accounts Receivable Turnover
6.37 7.47 6.60 8.52 7.63 7.15 6.99 7.85
Inventory Turnover
1.23 1.38 1.57 1.84 1.48 1.44 1.76 2.15
Fixed Asset Turnover
10.92 21.53 27.96 32.52 28.88 31.89 32.05 35.15
Accounts Payable Turnover
1.56 1.87 3.49 6.95 7.28 11.22 11.96 11.47
Days Sales Outstanding (DSO)
57.26 48.84 55.30 42.85 47.83 51.07 52.24 46.48
Days Inventory Outstanding (DIO)
297.64 264.59 232.67 198.18 246.95 253.56 207.55 169.95
Days Payable Outstanding (DPO)
234.18 194.86 104.52 52.54 50.13 32.53 30.51 31.82
Cash Conversion Cycle (CCC)
120.72 118.58 183.45 188.49 244.65 272.10 229.27 184.61
Capital & Investment Metrics
- - - - - - - -
Invested Capital
-1.26 6.62 5.46 7.66 12 13 17 11
Invested Capital Turnover
-6.59 5.76 3.02 4.49 4.17 4.70 4.69 5.73
Increase / (Decrease) in Invested Capital
0.00 7.87 -1.16 2.20 4.54 0.47 4.25 -5.79
Enterprise Value (EV)
159 123 173 142 218 156 107 52
Market Capitalization
52 148 217 186 220 162 119 48
Book Value per Share
($467.34) $2.71 $3.40 $1.39 $0.75 $0.77 $0.72 $0.16
Tangible Book Value per Share
($478.24) $2.46 $3.22 $1.23 $0.62 $0.68 $0.68 $0.12
Total Capital
-14 61 80 20 54 59 70 62
Total Debt
0.00 30 31 0.00 40 41 41 56
Total Long-Term Debt
0.00 30 31 0.00 40 41 41 56
Net Debt
-17 -24 -44 -44 -2.10 -6.21 -12 4.81
Capital Expenditures (CapEx)
0.06 0.20 0.17 0.63 0.87 0.60 -4.45 -0.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.58 3.03 2.23 4.55 8.03 8.03 9.80 6.76
Debt-free Net Working Capital (DFNWC)
14 58 77 48 50 55 62 58
Net Working Capital (NWC)
14 58 77 48 50 55 62 58
Net Nonoperating Expense (NNE)
8.64 9.01 11 13 17 16 14 15
Net Nonoperating Obligations (NNO)
12 -24 -44 -12 -2.10 -6.21 -12 4.81
Total Depreciation and Amortization (D&A)
1.25 0.58 0.53 0.54 1.19 0.81 1.01 1.01
Debt-free, Cash-free Net Working Capital to Revenue
-43.30% 19.64% 12.22% 15.44% 19.38% 13.74% 14.15% 8.42%
Debt-free Net Working Capital to Revenue
165.52% 373.05% 420.69% 164.55% 120.83% 93.68% 90.15% 71.76%
Net Working Capital to Revenue
165.52% 373.05% 420.69% 164.55% 120.83% 93.68% 90.15% 71.76%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($2.23) ($2.30) ($2.72) ($2.04) ($1.33) ($0.83)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 14.44M 14.47M 16.27M 22.87M 28.53M 46.95M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($2.23) ($2.30) ($2.72) ($2.04) ($1.33) ($0.83)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 14.44M 14.47M 16.27M 22.87M 28.53M 46.95M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($2.23) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 12.93M 14.55M 19.22M 24.65M 39.55M 44.74M
Normalized Net Operating Profit after Tax (NOPAT)
-14 -13 -18 -21 -27 -31 -29 -24
Normalized NOPAT Margin
-168.71% -86.84% -97.14% -69.97% -65.93% -52.78% -42.12% -29.43%
Pre Tax Income Margin
-254.92% -145.18% -156.67% -112.94% -106.95% -79.83% -54.81% -48.09%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
-4.82 -5.21 -7.09 -8.25 -7.39 -7.93 -6.18 -5.29
NOPAT to Interest Expense
-3.43 -3.72 -4.96 -5.73 -5.17 -5.91 -4.51 -3.85
EBIT Less CapEx to Interest Expense
-4.84 -5.27 -7.14 -8.43 -7.56 -8.05 -5.34 -5.16
NOPAT Less CapEx to Interest Expense
-3.45 -3.77 -5.01 -5.91 -5.34 -6.02 -3.67 -3.71
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -1.81% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for TELA Bio

This table displays calculated financial ratios and metrics derived from TELA Bio's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
24,649,595.00 24,655,371.00 24,713,798.00 - 39,551,098.00 39,554,989.00 39,616,440.00 40,341,535.00 44,740,371.00 44,766,146.00 44,894,757.00
DEI Adjusted Shares Outstanding
24,649,595.00 24,655,371.00 24,713,798.00 - 39,551,098.00 39,554,989.00 39,616,440.00 40,341,535.00 44,740,371.00 44,766,146.00 44,894,757.00
DEI Earnings Per Adjusted Shares Outstanding
-0.23 -0.51 -0.42 - -0.28 -0.25 -0.22 -0.22 -0.27 -0.25 -0.21
Growth Metrics
- - - - - - - - - - -
Revenue Growth
39.42% 11.02% 25.94% 3.83% 11.55% 25.52% 9.14% 18.24% 2.91% -4.49% -8.36%
EBITDA Growth
61.24% -18.78% 6.80% 31.46% -137.51% 23.48% 18.38% 21.24% -1.75% -5.08% 4.49%
EBIT Growth
59.85% -18.72% 6.18% 30.11% -130.84% 22.78% 18.01% 21.04% -1.67% -4.87% 4.08%
NOPAT Growth
57.12% -11.66% 8.01% 31.96% -116.99% 21.51% 19.34% 20.42% -0.52% -2.22% 3.49%
Net Income Growth
52.93% -16.77% 5.34% 28.56% -98.98% 21.25% 17.06% 1.81% -8.96% -13.49% -8.13%
EPS Growth
63.49% -10.87% 6.67% 66.00% -8.70% 56.86% 54.76% 0.00% 16.00% 9.09% 15.79%
Operating Cash Flow Growth
-24.28% 5.03% -28.92% 31.85% 32.39% 26.10% 36.34% 35.33% -14.86% -18.67% -51.98%
Free Cash Flow Firm Growth
33.12% 12.78% -2.19% -11.40% 27.00% 53.99% 89.07% 111.27% 67.82% 85.32% 32.94%
Invested Capital Growth
36.90% 14.98% 36.84% 33.51% -7.49% -9.31% -23.33% -34.24% -32.85% -37.20% -32.08%
Revenue Q/Q Growth
-2.32% -3.08% 17.81% -6.90% 4.94% 9.06% 2.44% 0.87% -8.67% 1.22% -1.72%
EBITDA Q/Q Growth
64.03% -169.11% 20.46% 10.98% -24.64% 13.30% 15.16% 14.09% -61.02% 10.47% 22.88%
EBIT Q/Q Growth
62.50% -160.31% 19.89% 10.62% -23.84% 12.92% 14.94% 13.93% -59.47% 10.18% 22.20%
NOPAT Q/Q Growth
60.69% -139.74% 19.06% 10.80% -25.35% 13.28% 16.82% 11.99% -58.33% 11.81% 21.47%
Net Income Q/Q Growth
56.08% -122.58% 17.68% 11.22% -22.33% 11.91% 13.30% -5.09% -35.75% 8.24% 17.40%
EPS Q/Q Growth
54.00% -121.74% 17.65% 59.52% -47.06% 12.00% 13.64% 10.53% -23.53% 4.76% 20.00%
Operating Cash Flow Q/Q Growth
-30.16% 25.63% 16.02% 16.16% -29.13% 18.71% 27.65% 14.85% -129.36% 16.02% 7.34%
Free Cash Flow Firm Q/Q Growth
9.44% -26.02% -8.71% 10.20% 40.66% 20.58% 74.17% 192.56% -269.44% 63.78% -18.03%
Invested Capital Q/Q Growth
41.36% -3.99% 1.20% -2.79% -2.05% -5.88% -14.45% -16.62% 0.03% -11.98% -7.48%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
68.28% 68.81% 67.83% 63.58% 67.56% 69.84% 67.52% 65.91% 65.69% 72.28% 64.92%
EBITDA Margin
-24.66% -68.49% -46.24% -44.21% -52.52% -41.75% -34.58% -29.45% -51.92% -45.93% -36.04%
Operating Margin
-29.07% -71.90% -49.40% -47.33% -56.54% -44.96% -36.51% -31.86% -55.23% -48.12% -38.45%
EBIT Margin
-26.07% -70.03% -47.62% -45.72% -53.96% -43.09% -35.78% -30.53% -53.31% -47.31% -37.45%
Profit (Net Income) Margin
-34.10% -78.30% -54.71% -52.17% -60.82% -49.13% -41.58% -43.32% -64.39% -58.38% -49.06%
Tax Burden Percent
100.00% 100.00% 100.00% 98.46% 100.46% 100.33% 100.00% 101.63% 100.49% 100.54% 101.12%
Interest Burden Percent
130.77% 111.81% 114.89% 115.90% 112.20% 113.65% 116.23% 139.63% 120.21% 122.75% 129.56%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-82.93% -202.77% -157.68% -155.26% -163.55% -144.63% -128.15% -127.71% -225.67% -212.09% -187.90%
ROIC Less NNEP Spread (ROIC-NNEP)
-116.85% -118.90% -288.61% -117.42% -564.12% -179.04% -146.86% 2.52% -292.10% -241.81% -206.39%
Return on Net Nonoperating Assets (RNNOA)
-89.75% 29.76% -69.30% 44.05% -34.08% -307.88% 1,104.16% -0.49% -333.80% 1,160.33% 407.21%
Return on Equity (ROE)
-172.68% -173.01% -226.98% -111.21% -197.63% -452.51% 976.00% -128.20% -559.47% 948.24% 219.31%
Cash Return on Invested Capital (CROIC)
-201.25% -183.18% -207.98% -190.17% -153.70% -149.41% -135.11% -127.26% -131.64% -141.89% -172.74%
Operating Return on Assets (OROA)
-25.21% -58.66% -46.59% -38.49% -51.55% -50.81% -48.11% -29.18% -58.56% -59.40% -52.71%
Return on Assets (ROA)
-32.97% -65.59% -53.53% -43.93% -58.11% -57.94% -55.92% -41.40% -70.73% -73.31% -69.06%
Return on Common Equity (ROCE)
-172.68% -173.01% -226.98% -111.21% -197.63% -452.51% 976.00% -128.20% -559.47% 948.24% 219.31%
Return on Equity Simple (ROE_SIMPLE)
-280.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.38 -8.10 -6.56 -5.85 -7.33 -6.36 -5.29 -4.65 -7.37 -6.50 -5.10
NOPAT Margin
-20.35% -50.33% -34.58% -33.13% -39.58% -31.47% -25.56% -22.30% -38.66% -33.68% -26.92%
Net Nonoperating Expense Percent (NNEP)
33.92% -83.87% 130.93% -37.84% 400.57% 34.41% 18.70% -130.23% 66.43% 29.71% 18.49%
Return On Investment Capital (ROIC_SIMPLE)
-6.14% -18.54% -18.89% -8.40% -12.34% -12.57% -12.28% -7.51% -14.54% -16.16% -16.09%
Cost of Revenue to Revenue
31.72% 31.19% 32.17% 36.42% 31.93% 30.16% 32.48% 32.27% 33.81% 27.23% 34.58%
SG&A Expenses to Revenue
23.06% 22.50% 19.43% 20.34% 20.71% 20.43% 19.08% 18.13% 21.86% 21.05% 26.30%
R&D to Revenue
14.41% 14.44% 10.91% 11.50% 13.71% 10.91% 11.35% 10.20% 12.29% 14.12% 8.46%
Operating Expenses to Revenue
97.34% 140.72% 117.23% 110.91% 124.10% 114.80% 104.03% 97.77% 120.92% 120.40% 103.37%
Earnings before Interest and Taxes (EBIT)
-4.33 -11 -9.03 -8.07 -9.99 -8.70 -7.40 -6.37 -10 -9.13 -7.10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.10 -11 -8.77 -7.80 -9.73 -8.43 -7.15 -6.15 -9.90 -8.86 -6.83
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
9.72 40.38 0.00 4.18 2.66 8.36 37.91 7.54 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
11.31 123.15 0.00 4.45 2.93 10.05 573.09 9.61 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.21 1.79 0.91 1.72 0.68 1.02 0.77 0.59 0.34 0.42 0.66
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
8.00 7.57 4.95 6.35 2.82 5.33 5.31 4.71 3.96 6.05 9.41
Enterprise Value to Revenue (EV/Rev)
2.27 2.01 1.26 1.55 0.66 1.10 0.92 0.65 0.55 0.74 1.09
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
2.83 14.22 -6.53 1.45 2.28 4.51 26.65 8.82 -10.74 -3.53 -2.29
Long-Term Debt to Equity
2.83 14.22 -6.53 1.45 2.28 4.14 26.65 8.82 -10.74 -3.53 0.00
Financial Leverage
0.77 -0.25 0.24 -0.38 0.06 1.72 -7.52 -0.19 1.14 -4.80 -1.97
Leverage Ratio
7.45 3.61 5.78 3.48 4.59 10.60 -24.31 4.83 11.39 -19.05 -4.83
Compound Leverage Factor
9.75 4.03 6.64 4.03 5.15 12.04 -28.25 6.75 13.69 -23.38 -6.25
Debt to Total Capital
73.87% 93.43% 118.08% 59.10% 69.49% 81.84% 96.38% 89.81% 110.27% 139.45% 177.47%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 6.59% 0.00% 0.00% 0.00% 0.00% 177.47%
Long-Term Debt to Total Capital
73.87% 93.43% 118.08% 59.10% 69.49% 75.25% 96.38% 89.81% 110.27% 139.45% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
26.13% 6.57% -18.08% 40.90% 30.51% 18.16% 3.62% 10.19% -10.27% -39.45% -77.47%
Debt to EBITDA
-1.19 -1.14 -1.16 -1.30 -1.11 -1.19 -1.25 -1.77 -1.77 -1.75 -1.77
Net Debt to EBITDA
-0.10 -0.40 -0.67 0.36 0.04 -0.18 -0.36 -0.15 -0.52 -0.80 -1.06
Long-Term Debt to EBITDA
-1.19 -1.14 -1.16 -1.30 -1.11 -1.10 -1.25 -1.77 -1.77 -1.75 0.00
Debt to NOPAT
-1.54 -1.50 -1.54 -1.72 -1.48 -1.59 -1.67 -2.36 -2.36 -2.36 -2.38
Net Debt to NOPAT
-0.13 -0.53 -0.89 0.48 0.06 -0.25 -0.47 -0.20 -0.69 -1.08 -1.42
Long-Term Debt to NOPAT
-1.54 -1.50 -1.54 -1.72 -1.48 -1.46 -1.67 -2.36 -2.36 -2.36 0.00
Altman Z-Score
-3.43 -5.50 -7.25 -3.21 -4.89 -5.66 -6.63 -4.88 -6.51 -8.04 -11.34
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.13 3.41 2.62 5.01 4.22 3.19 3.30 4.20 3.61 2.99 0.61
Quick Ratio
3.10 2.37 1.69 4.02 3.23 2.42 2.41 3.40 2.76 2.20 0.44
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-8.20 -10 -11 -10 -5.99 -4.76 -1.23 1.14 -1.93 -0.70 -0.82
Operating Cash Flow to CapEx
0.00% 0.00% -7,363.11% -3,963.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-6.16 -7.77 -8.36 -7.87 -4.91 -4.00 -1.02 0.45 -0.94 -0.34 -0.39
Operating Cash Flow to Interest Expense
-10.80 -8.04 -6.68 -5.87 -7.98 -6.65 -4.76 -1.93 -5.44 -4.52 -4.14
Operating Cash Flow Less CapEx to Interest Expense
-7.27 -7.99 -6.77 -6.02 -7.86 -6.48 -4.50 -1.85 -5.35 -4.40 -3.66
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.97 0.84 0.98 0.84 0.96 1.18 1.34 0.96 1.10 1.26 1.41
Accounts Receivable Turnover
7.60 7.62 7.12 6.99 6.94 7.41 6.85 7.85 7.97 7.66 7.61
Inventory Turnover
1.37 1.48 1.56 1.76 1.73 1.99 2.01 2.15 2.03 2.26 2.18
Fixed Asset Turnover
31.42 31.48 32.91 32.05 31.47 33.36 33.24 35.15 37.09 37.92 38.19
Accounts Payable Turnover
4.57 8.91 7.81 11.96 6.38 12.15 10.41 11.47 6.61 10.96 10.60
Days Sales Outstanding (DSO)
48.00 47.89 51.29 52.24 52.56 49.26 53.28 46.48 45.78 47.67 47.97
Days Inventory Outstanding (DIO)
267.34 246.69 234.21 207.55 211.11 183.36 181.85 169.95 180.13 161.54 167.30
Days Payable Outstanding (DPO)
79.84 40.99 46.72 30.51 57.25 30.05 35.07 31.82 55.24 33.30 34.42
Cash Conversion Cycle (CCC)
235.50 253.60 238.78 229.27 206.42 202.57 200.06 184.61 170.66 175.91 180.84
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
18 17 17 17 17 16 13 11 11 9.79 9.06
Invested Capital Turnover
4.08 4.03 4.56 4.69 4.13 4.60 5.01 5.73 5.84 6.30 6.98
Increase / (Decrease) in Invested Capital
4.83 2.24 4.68 4.25 -1.34 -1.60 -4.06 -5.79 -5.44 -5.80 -4.28
Enterprise Value (EV)
143 130 86 107 47 83 71 52 44 59 85
Market Capitalization
140 116 63 119 48 77 59 48 28 34 52
Book Value per Share
$0.58 $0.12 ($0.25) $0.72 $0.46 $0.23 $0.04 $0.16 ($0.12) ($0.35) ($0.55)
Tangible Book Value per Share
$0.50 $0.04 ($0.33) $0.68 $0.42 $0.19 $0.00 $0.12 ($0.14) ($0.38) ($0.57)
Total Capital
55 44 35 70 59 51 43 62 51 40 32
Total Debt
41 41 41 41 41 41 41 56 56 56 56
Total Long-Term Debt
41 41 41 41 41 38 41 56 56 56 0.00
Net Debt
3.52 14 24 -12 -1.56 6.41 12 4.81 16 26 34
Capital Expenditures (CapEx)
-4.70 -0.07 0.12 0.19 -0.14 -0.20 -0.31 -0.19 -0.19 -0.24 -1.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)
10 9.62 9.97 9.80 10 10 9.36 6.76 6.93 5.85 5.38
Debt-free Net Working Capital (DFNWC)
47 36 27 62 53 45 39 58 46 36 28
Net Working Capital (NWC)
47 36 27 62 53 42 39 58 46 36 -28
Net Nonoperating Expense (NNE)
2.28 4.50 3.82 3.36 3.93 3.57 3.32 4.39 4.90 4.76 4.20
Net Nonoperating Obligations (NNO)
3.52 14 24 -12 -1.56 6.41 12 4.81 16 26 34
Total Depreciation and Amortization (D&A)
0.23 0.25 0.26 0.27 0.27 0.27 0.25 0.23 0.26 0.27 0.27
Debt-free, Cash-free Net Working Capital to Revenue
16.30% 14.86% 14.53% 14.15% 14.57% 13.33% 12.14% 8.42% 8.57% 7.32% 6.88%
Debt-free Net Working Capital to Revenue
75.12% 55.79% 39.73% 90.15% 74.71% 59.77% 50.71% 71.76% 57.50% 45.39% 35.87%
Net Working Capital to Revenue
75.12% 55.79% 39.73% 90.15% 74.71% 55.34% 50.71% 71.76% 57.50% 45.39% -36.14%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.23) ($0.51) ($0.42) ($0.17) ($0.25) ($0.22) ($0.19) ($0.17) ($0.21) ($0.20) ($0.16)
Adjusted Weighted Average Basic Shares Outstanding
24.58M 24.66M 24.70M 28.53M 45.27M 45.37M 45.42M 46.95M 57.26M 57.41M 57.69M
Adjusted Diluted Earnings per Share
($0.23) ($0.51) ($0.42) ($0.17) ($0.25) ($0.22) ($0.19) ($0.17) ($0.21) ($0.20) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding
24.58M 24.66M 24.70M 28.53M 45.27M 45.37M 45.42M 46.95M 57.26M 57.41M 57.69M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
24.66M 24.71M 39.39M 39.55M 39.55M 39.62M 40.34M 44.74M 44.77M 44.89M 45.19M
Normalized Net Operating Profit after Tax (NOPAT)
-8.68 -8.10 -6.56 -5.85 -7.33 -6.36 -5.29 -4.65 -7.37 -6.50 -5.10
Normalized NOPAT Margin
-52.31% -50.33% -34.58% -33.13% -39.58% -31.47% -25.56% -22.30% -38.66% -33.68% -26.92%
Pre Tax Income Margin
-34.10% -78.30% -54.71% -52.99% -60.54% -48.97% -41.58% -42.63% -64.08% -58.07% -48.52%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-3.25 -8.47 -6.72 -6.29 -8.20 -7.32 -6.16 -2.52 -4.95 -4.40 -3.38
NOPAT to Interest Expense
-2.54 -6.08 -4.88 -4.56 -6.01 -5.35 -4.40 -1.84 -3.59 -3.13 -2.43
EBIT Less CapEx to Interest Expense
0.28 -8.42 -6.81 -6.44 -8.08 -7.15 -5.90 -2.45 -4.86 -4.28 -2.90
NOPAT Less CapEx to Interest Expense
0.99 -6.03 -4.97 -4.71 -5.90 -5.18 -4.14 -1.77 -3.50 -3.02 -1.95
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

TELA Bio’s financial statements show modest revenue growth and improving gross margins, but the company remains deeply unprofitable and cash-flow negative. Revenue reached $19.3 million in Q2 2026, up from $16.1 million in Q2 2024 and $15.1 million in Q3 2023. However, revenue has remained in a relatively narrow range near $19 million to $21 million over the past several quarters, while operating losses have persisted.

  • Gross margin improved: Q2 2026 gross profit was $13.9 million, representing a margin of approximately 72.3%, compared with 69.8% in Q2 2025 and 68.8% in Q2 2024. This suggests better product economics or a more favorable sales mix.
  • Quarterly revenue remains above early-2024 levels: Q2 2026 revenue increased approximately 19.9% from Q2 2024 and 28.2% from Q3 2023, although growth has not been consistent from quarter to quarter.
  • Operating cash burn improved sequentially: Cash used in operating activities declined from $11.2 million in Q1 2026 to $9.4 million in Q2 2026. The Q2 figure was also below the $10.7 million used in Q2 2025.
  • Liquidity is supported by current assets: TELA Bio reported $54.5 million of current assets and $18.2 million of current liabilities at June 30, 2026, implying a current ratio near 3.0. This provides a cushion for near-term obligations despite ongoing cash burn.
  • Revenue growth has stalled recently: Q2 2026 revenue increased only 1.2% from Q1 2026 and declined 4.5% from Q2 2025. The company will likely need renewed top-line growth to leverage its improving gross margin.
  • Inventory declined but remains significant: Inventory fell to $11.1 million in Q2 2026 from $12.2 million in Q1 2026 and $13.4 million in Q1 2024. Further reductions could help release working capital, but inventory levels remain material relative to quarterly revenue.
  • Net losses remain substantial: TELA Bio posted a $11.3 million net loss in Q2 2026, following losses of $12.3 million in Q1 2026 and $9.0 million in Q4 2025. The company has reported losses in every quarter provided.
  • Operating expenses continue to exceed gross profit: Q2 2026 operating expenses totaled $23.2 million, including $16.4 million of marketing expense, compared with $13.9 million of gross profit. This produced an operating loss of $9.3 million.
  • Cash is declining rapidly: Cash and equivalents fell to $30.4 million at June 30, 2026, from $39.5 million at March 31, 2026 and $42.8 million at March 31, 2025. At the recent operating burn rate, the cash balance could support only several quarters without improved profitability or additional financing.
  • Leverage and shareholder capital remain concerns: Long-term debt totaled $56.1 million at the end of Q2 2026, while shareholders’ equity was negative $15.9 million. The weighted-average share count also increased to 57.4 million in Q2 2026 from 24.7 million in Q2 2024, indicating significant dilution over the period.

Overall, TELA Bio has made progress in gross margin and has maintained a sizable current-asset base, but those positives are outweighed by continuing losses, heavy marketing spending, negative operating cash flow, rising debt and negative book equity. Investors should focus on whether revenue can accelerate enough to absorb operating expenses and whether the company can reduce cash burn before another financing becomes necessary.

11/21/26 07:40 PM ETAI Generated. May Contain Errors.

TELA Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TELA Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

TELA Bio's net income appears to be on a downward trend, with a most recent value of -$38.83 million in 2025, falling from -$21.09 million in 2018. The previous period was -$37.84 million in 2024. See where experts think TELA Bio is headed by visiting TELA Bio's forecast page.

TELA Bio's total operating income in 2025 was -$33.76 million, based on the following breakdown:
  • Total Gross Profit: $54.34 million
  • Total Operating Expenses: $88.10 million

Over the last 7 years, TELA Bio's total revenue changed from $8.27 million in 2018 to $80.28 million in 2025, a change of 870.2%.

In the past 12 quarters, TELA Bio's cash and equivalents has ranged from $17.30 million in Q3 2024 to $58.20 million in Q3 2023, and is currently $22.66 million as of their latest financial filing in Q3 2026.

TELA Bio had total debt of $55.65 million at the end of 2025, a 35.3% increase from 2024, and none in 2018.

Over the last 7 years, TELA Bio's book value per share changed from -467.34 in 2018 to 0.16 in 2025.



Financial statements for NASDAQ:TELA last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners